epirubicin + ifosfamide

Epirubicin + ifosfamide is a combination chemotherapy regimen consisting of two cytotoxic agents, epirubicin and ifosfamide. Epirubicin is an anthracycline antibiotic that intercalates into DNA, inhibiting topoisomerase II and generating free radicals, leading to DNA damage and apoptosis in rapidly dividing cells. Ifosfamide is an alkylating agent of the oxazaphosphorine class that crosslinks DNA strands, thereby preventing cell replication and inducing cell death. This combination has been primarily studied for the treatment of advanced or metastatic soft tissue sarcomas, where it has demonstrated efficacy with acceptable toxicity profiles[1][2][3]. The regimen may also be used in other solid tumors as part of multi-agent protocols.